LDS/Medical Tests/Age Related Macular Degeneration Gene Mutation Analysis

Age Related Macular Degeneration Gene Mutation Analysis

Age-related macular degeneration (AMD) is the most common cause of visual loss and blindness in older people (older than 65). The disease affects the center of the retina, called the macula, which is responsible for central vision. Two types of AMD are distinguished: dry (non-exudative or atrophic) and wet (exudative or neovascular) form.

The dry form is more common, and counts for more than 80% of all cases. The dry form is characterized by a buildup of yellowish deposits called drusen beneath the retina which leads to progressive vision loss. The condition typically affects vision in both eyes, although vision loss often occurs in one eye before the other.

The wet form of age-related macular degeneration is associated with severe vision loss and is often characterized by the growth of abnormal, fragile blood vessels underneath the macula. These vessels leak blood and fluid, which damages the macula and makes central vision appear blurry and distorted. AMD is considered to be a genetic complex disease in which multiple genes and environmental factors play a role in pathogenesis.

Genetic testing that screens for the presence of the two mutations, Y402H polymorphism in the CFH gene on chromosome 1 and p.A69S polymorphism of the ARMS2 gene on chromosome 10q26 is most commonly used to screen for carriers and to help assess the risk of developing the disease. Heterozygous mutation of CFH is associated with a 2.5 to 4.6 times increased risk of AMD while homozygotes have 3.3 to 7.4 times increased risk. Other mutations of the CFH gene, as well as mutations in other genes regulating the complement pathway (including the SERPING1 and CFB genes), may also result in an increased incidence of AMD.

  • Diagnosis of age-related macular degeneration
  • Screening individuals with a positive family history of macular degeneration
  • Diagnosis of susceptibility to macular degeneration
Positive for Y492H and/or A69S heterozygous and/or homozygous are associated with increased risk of developing AMD. Compound heterozygous or homozygous for either also increase the risk.

Negative for mutation analyzed (No mutation detected)

Polymerase Chain Reaction (PCR) with allele specific primer extension (ASPE), Real-time PCR, Sequencing.

Whole blood collected in EDTA (lavender top) tube.

Stability

  • Room: 5 days
  • Refrigerated: 7 days
Eye exam, Retina ultrasound, Comprehensive Metabolic Panel, CBC, CEA, TNF-Alpha, Interleukin-1 BETA, C-reactive protein (CRP), Interleukin-6, Vitamin K, MTHFR.
5-10 days
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login